Cautious on Yahoo! ...
Health Care: Drugs
Vertex Pharmaceuticals (VRTX: NASDAQ)
$77.67 -0.81 | -1.03%
05/24/13 - 10:50 AM ET
Latest Dividend:0.00
Latest Dividend Yield:0.00%
Dividend Ex-Date:08/24/00
Price Earnings Ratio:n/a
Price Earnings Comparisons:
| VRTX | Sector Avg. | S&P 500 |
|---|---|---|
| n/a | 0.00 | 17.70 |
Price Performance History (% change):
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| 70.83 | 24.39 | 129.87 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | 8.30 | 13.99 | 1.44 |
| Net Income | -100.00 | -0.92 | 0.00 |
| EPS | -100.00 | -0.87 | 0.00 |
Earnings for VRTX:
| EBITDA | 42.37M |
| REVENUE | 1.53B |
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $-0.21 | $-0.26 | $-2.13 | $-1.42 |
| Number of Analysts | 7 | 7 | 10 | 10 |
| High Estimate | $-0.12 | $-0.19 | $-1.00 | $0.15 |
| Low Estimate | $-0.32 | $-0.38 | $-2.56 | $-2.69 |
| Prior Year | $0.32 | $0.00 | $0.68 | $-2.13 |
| Growth Rate (Year over Year) | -164.73% | n.a.% | -412.79% | 33.29% |
Portfolios with VRTX
- Portfolio NameUser Type
- UserDC
- UserPortfolio
- ProDaniel Loeb - Third Point
- UserMike Fatah's Mega Stock Por...
- Contributor10 Companies That Prove Sto...
- ContributorRelative Strength Trades fo...
- ContributorEarnings Short Squeeze Play...
- ProD.E. Shaw
- ContributorEarnings Short Squeeze Play...
- Contributor10 Hep C Stocks on Wall Str...
Latest VRTX Headlines from TheStreet
- 5 Stocks Underperforming Today In The Drugs Industry 05.20.13 | 01:05 pm
- Vertex Pharmaceuticals (VRTX): Today's Featured Health Care Laggard 05.16.13 | 05:05 pm
- 3 Stocks Underperforming Today In The Drugs Industry 05.15.13 | 01:05 pm
- 3 Stocks Improving Performance Of The Health Care Sector 05.06.13 | 01:05 pm
- Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Laggard 05.03.13 | 05:05 pm
- Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Laggard 04.26.13 | 05:04 pm
- Vertex CFO Rings Register On $35 Million Insider Sale 04.24.13 | 07:04 am
- 'Mad Money' Lightning Round: Apache Is a Dog 04.24.13 | 06:04 am
- Cramer's 'Mad Money' Recap: Looking for Winners in Unlikely Places 04.23.13 | 08:04 pm
- 4 Stocks Pushing The Drugs Industry Downward 04.22.13 | 01:04 pm
Press Releases for VRTX
- VX-787 Showed Significant Antiviral Activity And Reduced The Severity And Duration Of Influenza Symptoms In Phase 2 Challenge Study - Business Wire 03.04.13 | 08:03 am
- Vertex Announces Webcasts Of Its Presentations At Two Investor Conferences - Business Wire 02.27.13 | 04:02 pm
- Vertex Announces Initiation Of Pivotal Phase 3 Program Of VX-809 In Combination With Ivacaftor For The Treatment Of People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation - Business Wire 02.26.13 | 04:02 pm
- Republic Of Ireland Approves Funding For KALYDECO™ (ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis, For People With A Specific Genetic Mutation (G551D) - Business Wire 02.01.13 | 12:02 pm
- Vertex Reports Full-Year And Fourth Quarter 2012 Financial Results And Provides Updates On Key Development Programs - Business Wire 01.29.13 | 04:01 pm
- Vertex To Report Fourth Quarter And Full Year 2012 Financial Results On Tuesday, January 29 - Business Wire 01.15.13 | 04:01 pm
- Vertex Outlines Corporate Strategy And Defines Key 2013 Business Priorities - Business Wire 01.06.13 | 05:01 pm
- NHS In England Funds KALYDECO™ (ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis, For People With A Specific Genetic Mutation (G551D) - Business Wire 12.19.12 | 09:12 am
- Vertex Announces Update To U.S. Prescribing Information For INCIVEK® (telaprevir) - Business Wire 12.19.12 | 08:12 am
- Health Canada Approves KALYDECO™ (ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People With A Specific Genetic Mutation (G551D) - Business Wire 12.03.12 | 08:12 am
Partner Headlines for VRTX
- Market Close Report: NASDAQ Composite index closes at 3,206.06 up 39.70 points - NASDAQ 04.19.13 | 08:04 pm
- Stocks Up, Dow Turns Positive; Leaders Catch An Updraft - Investor's Business Daily 04.19.13 | 12:04 pm
- UPDATE: Credit Suisse Raises PT on Vertex Pharmaceuticals on Cystic Fibrosis Franchise De-Risking - Benzinga 04.19.13 | 09:04 am
- Futures Geared For Higher Open; Vertex, Google, Chipotle Rumble - Investor's Business Daily 04.19.13 | 08:04 am
- Stocks Take Another Drubbing, But Google Rises After Hours - Investor's Business Daily 04.18.13 | 05:04 pm
- Regeneron Pharmaceuticals Inc (REGN): Today's Most Compelling Buy - NASDAQ 03.14.13 | 04:03 pm
- Market Close Report: NASDAQ Composite index closes at 3,244.37 up 12.28 points - NASDAQ 03.08.13 | 09:03 pm
- Gilead Stock Hits New High As HCV Drug Keeps Rocking - Investor's Business Daily 02.19.13 | 04:02 pm
- RIM, Green Mountain and Other Top Performing Nasdaq Stocks in November - Benzinga 12.01.12 | 01:12 pm
- Celgene, Regeneron Pharmaceutical Lead Biomed Group - Investor's Business Daily 11.30.12 | 05:11 pm
